{"drugs":["Decavac","Tenivac","Tetanus and Diphtheria Toxoids, Adsorbed"],"mono":{"0":{"id":"183530-s-0","title":"Generic Names","mono":"Tetanus and Diphtheria Toxoids, Adsorbed"},"1":{"id":"183530-s-1","title":"Dosing and Indications","sub":{"0":{"id":"183530-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Tetanus diphtheria vaccination:<\/b> (Decavac(R)) primary immunization is a 3-dose series, each dose is 0.5 mL IM; administer dose 1 and 2 at least 4 weeks apart and administer dose 3 at least 6 months after second injection; routine booster every 10 years thereafter<\/li><li><b>Tetanus diphtheria vaccination:<\/b> (Tenivac(R)) primary immunization is a 3-dose series, each dose is 0.5 mL IM; administer first and second dose 2 months apart and administer third dose 6 to 8 months after second injection; routine booster every 10 years thereafter<\/li><\/ul>"},"1":{"id":"183530-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Tetanus diphtheria vaccination:<\/b> (6 weeks up to 7 years; pediatric formulation) primary immunization is a 5-dose series, each dose is 0.5 mL IM; recommended ages for administration are 2, 4, 6, 15 to 18 months, and 4 to 6 years<\/li><li><b>Tetanus diphtheria vaccination:<\/b> (7 years or older; Tenivac(R)) primary immunization is a 3-dose series, each dose is 0.5 mL IM; administer first and second dose 2 months apart and administer third dose 6 to 8 months after second injection; routine booster at age 11 to 12 years and every 10 years thereafter<\/li><li><b>Tetanus diphtheria vaccination:<\/b> (7 years or older; Decavac(R)) primary immunization is a 3 dose series, each dose is 0.5 mL IM; administer dose 1 and 2 at least 4 weeks apart and administer dose 3 at least 6 months after second injection; routine booster at age 11 to 12 years and every 10 years thereafter<\/li><\/ul>"},"3":{"id":"183530-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Tetanus diphtheria vaccination<br\/>"}}},"3":{"id":"183530-s-3","title":"Contraindications\/Warnings","sub":[{"id":"183530-s-3-9","title":"Contraindications","mono":"severe allergic reaction (eg, anaphylaxis) to a previous dose of any diphtheria toxoid- or tetanus toxoid-containing vaccine or to any component of the vaccine <br\/>"},{"id":"183530-s-3-10","title":"Precautions","mono":"<ul><li>Immunologic:<\/li><li>-- avoid administering tetanus-toxoid containing vaccines more frequently than every 10 years in patients with a past history of arthus type hypersensitivity reactions to prior tetanus toxoid-containing vaccin<\/li><li>-- acute hypersensitivity or anaphylactic reaction may occur; ensure adequate treatment is available including epinephrine (1:1000) solution<\/li><li>-- tip caps of the prefilled syringes contain natural rubber latex; allergic reaction may occur in latex-sensitive individuals<\/li><li>-- desired immune response may not be achieved in immunocompromised patients, including those receiving immunosuppressive therapy<\/li><li>Neurologic:<\/li><li>--brachial neuritis and Guillain-Barre syndrome have been associated with tetanus toxoid administration<\/li><li>-- if Guillain-Barre has occurred within 6 weeks of administering prior tetanus-toxoid containing vaccines, weigh the potential risk versus benefit prior to vaccination with any other tetanus-toxoid containing vaccines<\/li><\/ul>"},{"id":"183530-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"183530-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"183530-s-4","title":"Drug Interactions","sub":{"1":{"id":"183530-s-4-14","title":"Major","mono":"<ul>Cyclosporine (theoretical)<\/ul>"},"2":{"id":"183530-s-4-15","title":"Moderate","mono":"<ul><li>Chloramphenicol (probable)<\/li><li>Meningococcal Vaccine, Tetanus Toxoid Conjugate Quadrivalent (established)<\/li><\/ul>"}}},"5":{"id":"183530-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (pediatrics, 19.7% to 25.6%; adults, 15.8% to 21.6%), Injection site pain (pediatric, 71% to 80.1%; adult, 29.4% to 74.9%), Swelling at injection site (12.1% to 18.3%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (10.2% to 11.3%), Nausea (pediatric, 12.3%; adult, 7.9%)<\/li><li><b>Musculoskeletal:<\/b>Generalized acute body pains, Inflamed joint (7% to 11.7%), Muscle weakness (pediatric, 32.3%; adult, 4.9% to 17.4%)<\/li><li><b>Neurologic:<\/b>Headache (pediatric, 23% to 40.4%; adult, 10.8% to 34.1%)<\/li><li><b>Other:<\/b>Fatigue (20.7 to 27.3%), Malaise (8.8% to 17%), Shivering (pediatric, 12.6%; adult, 6.6%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Erythema multiforme<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction, Hypersensitivity reaction, arthus type<\/li><li><b>Neurologic:<\/b>Brachial neuritis, Guillain-Barr  syndrome, Seizure<\/li><\/ul>"},"6":{"id":"183530-s-6","title":"Drug Name Info","sub":[{"id":"183530-s-6-17","title":"US Trade Names","mono":"<ul><li>Decavac<\/li><li>Tenivac<\/li><\/ul>"},{"id":"183530-s-6-18","title":"Synonyms","mono":"<ul><li>Diphtheria and Tetanus Toxoids<\/li><li>Td - Tetanus and Diphtheria Toxoids<\/li><li>DT - Diphtheria and Tetanus Toxoids<\/li><\/ul>"},{"id":"183530-s-6-19","title":"Class","mono":"<ul><li>Toxoid<\/li><li>Vaccine<\/li><\/ul>"},{"id":"183530-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},{"id":"183530-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}]},"7":{"id":"183530-s-7","title":"Mechanism Of Action","mono":"<ul><li>Diphtheria toxoid component helps reduce the risk of developing diphtheria and protects immunized persons for at least 10 years. The vaccine also enables vaccine recipients to develop only a mild form of the disease in case they do develop diphtheria. It induces the development of neutralizing antibodies to diphtheria toxin.<\/li><li>Tetanus toxoid component protects adequately immunized persons against tetanus for at least 10 years. The toxoid stimulates the development of neutralizing antibodies to tetanus toxin.<\/li><\/ul>"},"9":{"id":"183530-s-9","title":"Administration","mono":"<b>Intramuscular<\/b><br\/><ul><li>for IM use only; do not administer IV  or SUBQ<\/li><li>shake well prior to use; discard syringe\/vial if vaccine cannot be resuspended<\/li><li>do not remove the rubber stopper or metal seal holding it in place<\/li><li>(6 weeks up to 7 years) preferred injection sight is the anterolateral aspect of the mid-thigh or the deltoid; do not inject into gluteal area or areas containing a major nerve trunk<\/li><li>(7 years or older) preferred injection site is the deltoid; do not inject into gluteal area or areas containing a major nerve trunk<\/li><li>use a separate syringe and injection site when given concurrently with tetanus immune globulin<\/li><\/ul>"},"10":{"id":"183530-s-10","title":"Monitoring","mono":"No specific monitoring has been determined.<br\/>"},"11":{"id":"183530-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Intramuscular Suspension: (Diphtheria Toxoid, Adsorbed - Tetanus Toxoid) 2 Lf U\/0.5 ML-2 Lf U\/0.5 ML, 2 Lf U\/0.5 ML-5 Lf U\/0.5 ML, 25 Lf U\/0.5 ML-5 Lf U\/0.5 ML<br\/><\/li><li><b>Tenivac<\/b><br\/>Intramuscular Suspension: (Diphtheria Toxoid, Adsorbed - Tetanus Toxoid) 2 Lf U\/0.5 ML-5 Lf U\/0.5 ML<br\/><\/li><\/ul>"},"13":{"id":"183530-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to report latex sensitivity prior to administration, as syringe contains latex.<\/li><li>Tell patient that vaccine may not provide complete protection against tetanus or diphtheria, particularly in the elderly (aged 65 or older).<\/li><li>Advise patient and caregivers on importance of completing the primary immunization series or receiving booster doses.<\/li><li>Direct patient or caregiver to report any suspected adverse reactions.<\/li><li>Side effects may include pain, headache, erythema or swelling at the injection site, malaise, muscle weakness, body aches, fatigue, or diarrhea.<\/li><\/ul>"}}}